Tenaya Therapeutics signed a discovery collaboration with Alnylam Pharmaceuticals that provides $10 million up front and up to $1.13 billion in milestone payments if up to 15 delivered genetic targets lead to approved RNAi therapies. The pact is Tenaya’s first major cardiovascular collaboration with a big‑pharma RNAi specialist. Tenaya will continue advancing its internal gene therapy programs (TN‑201, TN‑401) while contributing targets; Alnylam brings RNAi development and commercialization capabilities. The deal aligns human genetics‑driven target discovery with RNAi therapeutic chemistry and delivery expertise. For cardiovascular R&D, the agreement signals growing industry willingness to pair discovery platforms with RNAi execution to de‑risk novel target development in a historically challenging therapeutic area.